Advances in the monitoring of anti-P2Y₁₂ therapy

References

• Cattaneo M. The platelet P2Y receptor for adenosine diphosphate: Congenital and drug-induced defects. Blood 2011; 117(7)2102–2112
   PubMed Web of Science ®Google Scholar
• Gurbel PA, Tantry US. Platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents. Circulation 2012; 125(10)1276–1287
   PubMed Web of Science ®Google Scholar
• Cattaneo M. Response variability to clopidogrel: Is tailored treatment, based on laboratory testing, the right solution?. J Thromb Haemost 2012; 10(3)327–336
   PubMedGoogle Scholar
• Cattaneo M. New P2Y(12) inhibitors. Circulation 2010; 121(1)171–179
   PubMed Web of Science ®Google Scholar
• Sibbing D, Byrne RA, Bernlochner I, Kastrati A. High platelet reactivity and clinical outcome – Fact and fiction. Thromb Haemost 2011; 106(2)191–202
   PubMed Web of Science ®Google Scholar
• Small DS, Farid NA, Payne CD, Konkoy CS, Jakubowski JA, Winters KJ, Salazar DE. Effect of intrinsic and extrinsic factors on the clinical pharmacokinetics and pharmacodynamics of prasugrel. Clin Pharmacokinet 2010; 49(12)777–798
   PubMed Web of Science ®Google Scholar
• Michelson AD. New P2Y12 antagonists. Curr Opin Hematol 2009; 16(5)371–377
   PubMedGoogle Scholar
• Jakubowski JA. Beyond platelet functional testing: Value in the aggregate. Biomark Med 2011; 5(1)5–8
   PubMedGoogle Scholar
• Bonello L, Tantry US, Marcucci R, Blindt R, Angiolillo DJ, Becker R, Bhatt DL, Cattaneo M, Collet JP, Cuisset T, et al. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol 2010; 56(12)919–933
   PubMed Web of Science ®Google Scholar
• Sibbing D, Steinhubl SR, Schulz S, Schomig A, Kastrati A. Platelet aggregation and its association with stent thrombosis and bleeding in clopidogrel-treated patients: Initial evidence of a therapeutic window. J Am Coll Cardiol 2010; 56(4)317–318
   PubMed Web of Science ®Google Scholar
• Smock KJ, Saunders PJ, Rodgers GM, Johari V. Laboratory evaluation of clopidogrel responsiveness by platelet function and genetic methods. Am J Hematol 2011; 86(12)1032–1034
   PubMedGoogle Scholar
• Wright RS, Anderson JL, Adams CD, Bridges CR, Casey DE, Jr, Ettinger SM, ., Fesmire FM, Ganiats TG, Jneid H, Lincoff AM, et al. 2011) ACCF/AHA Focused Update of the Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction (Updating the (2007) Guideline): A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2011; 123(18)2022–2060
   PubMed Web of Science ®Google Scholar
• Krishna V, Diamond GA, Kaul S. The role of platelet reactivity and genotype testing in the prevention of atherothrombotic cardiovascular events remains unproven. Circulation 2012; 125(10)1288–1303
   PubMed Web of Science ®Google Scholar
• Harrison P. Platelet function analysis. Blood Rev 2005; 19(2)111–123
   PubMed Web of Science ®Google Scholar
• Price MJ. Bedside evaluation of thienopyridine antiplatelet therapy. Circulation 2009; 119(19)2625–2632
   PubMedGoogle Scholar
• Harrison P. Progress in the assessment of platelet function. Br J Haematol 2000; 111(3)733–744
   PubMedGoogle Scholar
• Harrison P, Frelinger AL, 3rd, Furman MI, Michelson AD. Measuring antiplatelet drug effects in the laboratory. Thromb Res 2007; 120(3)323–336
   PubMed Web of Science ®Google Scholar
• Geiger J, Teichmann L, Grossmann R, Aktas B, Steigerwald U, Walter U, Schinzel R. Monitoring of clopidogrel action: Comparison of methods. Clin Chem 2005; 51(6)957–965
   PubMedGoogle Scholar
• Edwards A, Jakubowski JA, Rechner AR, Sugidachi A, Harrison P. Evaluation of the INNOVANCE PFA P2Y test cartridge: Sensitivity to P2Y(12) blockade and influence of anticoagulant. Platelets 2012; 23(2)106–115
   PubMed Web of Science ®Google Scholar
• Judge HM, Buckland RJ, Sugidachi A, Jakubowski JA, Storey RF. Relationship between degree of P2Y12 receptor blockade and inhibition of P2Y12-mediated platelet function. Thromb Haemost 2010; 103(6)1210–1217
   PubMedGoogle Scholar
• Breet NJ, van Werkum JW, Bouman HJ, Kelder JC, Ruven HJ, Bal ET, Deneer VH, Harmsze AM, van der Heyden JA, Rensing BJ, et al. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. JAMA 2010; 303(8)754–762
   PubMed Web of Science ®Google Scholar
• Michelson AD. Methods for the measurement of platelet function. Am J Cardiol 2009; 103(3 Suppl)20A–26A
   Web of Science ®Google Scholar
• Price MJ, Barker CM. Functional testing methods for the antiplatelet effect of P2Y12 receptor antagonists. Biomark Med 2011; 5(1)43–51
   PubMedGoogle Scholar
• Born GV. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 1962; 194: 927–929
   PubMed Web of Science ®Google Scholar
• O’Brien JM. Platelet aggregation. II. Some results from a new method of study. J Clin Pathol 1962; 15: 452–481
   PubMed Web of Science ®Google Scholar
• Born GV, Cross MJ. The aggregation of blood platelets. J Physiol 1963; 168: 178–195
   PubMed Web of Science ®Google Scholar
• Zhou L, Schmaier AH. Platelet aggregation testing in platelet-rich plasma: Description of procedures with the aim to develop standards in the field. Am J Clin Pathol 2005; 123(2)172–183
   PubMed Web of Science ®Google Scholar
• Hayward CP, Moffat KA, Raby A, Israels S, Plumhoff E, Flynn G, Zehnder JL. Development of North American consensus guidelines for medical laboratories that perform and interpret platelet function testing using light transmission aggregometry. Am J Clin Pathol 2010; 134(6)955–963
   PubMed Web of Science ®Google Scholar
• Paniccia R, Antonucci E, Maggini N, Miranda M, Romano E, Gori AM, Marcucci R, Prisco D, Abbate R. Light transmittance aggregometry induced by different concentrations of adenosine diphosphate to monitor clopidogrel therapy: A methodological study. Ther Drug Monit 2011; 33(1)94–98
   PubMedGoogle Scholar
• Gurbel PA, Bliden KP, Etherington A, Tantry US. Assessment of clopidogrel responsiveness: Measurements of maximum platelet aggregation, final platelet aggregation and their correlation with vasodilator-stimulated phosphoprotein in resistant patients. Thromb Res 2007; 121(1)107–115
   PubMedGoogle Scholar
• Labarthe B, Theroux P, Angioi M, Ghitescu M. Matching the evaluation of the clinical efficacy of clopidogrel to platelet function tests relevant to the biological properties of the drug. J Am Coll Cardiol 2005; 46(4)638–645
   PubMedGoogle Scholar
• Lordkipanidze M, Pharand C, Palisaitis DA, Schampaert E, Diodati JG. Insights into the interpretation of light transmission aggregometry for evaluation of platelet aggregation inhibition by clopidogrel. Thromb Res 2009; 124(5)546–553
   PubMedGoogle Scholar
• Breet NJ, van Werkum JW, Bouman HJ, Kelder JC, ten Berg JM, Hackeng CM. Both peak and late aggregation are capable of identifying patients at risk for atherothrombotic events. Thromb Haemost 2011; 105(1)197–199
   PubMedGoogle Scholar
• Gurbel PA, Bliden KP, Hayes KM, Yoho JA, Herzog WR, Tantry US. The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting. J Am Coll Cardiol 2005; 45(9)1392–1396
   PubMed Web of Science ®Google Scholar
• Gurbel PA, Bliden KP, Samara W, Yoho JA, Hayes K, Fissha MZ, Tantry US. Clopidogrel effect on platelet reactivity in patients with stent thrombosis: Results of the CREST Study. J Am Coll Cardiol 2005; 46(10)1827–1832
   PubMed Web of Science ®Google Scholar
• Michelson AD. Platelet function testing in cardiovascular diseases. Circulation 2004; 110(19)e489–e493
   PubMed Web of Science ®Google Scholar
• Rand ML, Leung R, Packham MA. Platelet function assays. Transfus Apher Sci 2003; 28(3)307–317
   PubMed Web of Science ®Google Scholar
• Harrison P, Mackie I, Mumford A, Briggs C, Liesner R, Winter M, Machin S. Guidelines for the laboratory investigation of heritable disorders of platelet function. Br J Haematol 2011; 155(1)30–44
   PubMed Web of Science ®Google Scholar
• Christie DJ, Avari T, Carrington LR, Cohen E, DeBiase BA, Harrison P, Kickler T, Kottke-Marchant K, Ledford-Kraemer MR, Rand ML, et al. Platelet function testing by aggregometry: Approved guideline. Clinical and Laboratory Standards Institute, Wayne, PA 2008; 28
   Google Scholar
• minutes SSC, [http://isth.org/default/index.cfm/ssc1/ssc-minutes/]
   Google Scholar
• Breet NJ, van Werkum JW, Bouman HJ, Kelder JC, ten Berg JM, Hackeng CM. Do not adjust the platelet count in light transmittance aggregometry when predicting thrombotic events after percutaneous coronary intervention. J Thromb Haemost 2010; 8(10)2326–2328
   PubMedGoogle Scholar
• Aleil B, Ravanat C, Cazenave JP, Rochoux G, Heitz A, Gachet C. Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases. J Thromb Haemost 2005; 3(1)85–92
   PubMed Web of Science ®Google Scholar
• Kreutz RP, Nystrom P, Kreutz Y, Miao J, Kovacs R, Desta Z, Flockhart DA, Jin Y. Inhibition of platelet aggregation by prostaglandin E1 (PGE1) in diabetic patients during therapy with clopidogrel and aspirin. Platelets 2012, Epub ahead of print
   PubMedGoogle Scholar
• Michelson AD, Cattaneo M, Eikelboom JW, Gurbel P, Kottke-Marchant K, Kunicki TJ, Pulcinelli FM, Cerletti C, Rao AK. Aspirin resistance: Position paper of the Working Group on Aspirin Resistance. J Thromb Haemost 2005; 3(6)1309–1311
   PubMed Web of Science ®Google Scholar
• Parodi G, Marcucci R, Valenti R, Gori AM, Migliorini A, Giusti B, Buonamici P, Gensini GF, Abbate R, Antoniucci D. High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI. JAMA 2011; 306(11)1215–1223
   PubMed Web of Science ®Google Scholar
• Sun B, Tandon NN, Yamamoto N, Yoshitake M, Kambayashi J. Luminometric assay of platelet activation in 96-well microplate. Biotechniques 2001; 31(5)1174, 1176, 1178 passim
   PubMedGoogle Scholar
• Armstrong PC, Dhanji AR, Truss NJ, Zain ZN, Tucker AT, Mitchell JA, Warner TD. Utility of 96-well plate aggregometry and measurement of thrombi adhesion to determine aspirin and clopidogrel effectiveness. Thromb Haemost 2009; 102(4)772–778
   PubMed Web of Science ®Google Scholar
• Moran N, Kiernan A, Dunne E, Edwards RJ, Shields DC, Kenny D. Monitoring modulators of platelet aggregation in a microtiter plate assay. Anal Biochem 2006; 357(1)77–84
   PubMedGoogle Scholar
• Chan MV, Armstrong PC, Papalia F, Kirkby NS, Warner TD. Optical multichannel (optimul) platelet aggregometry in 96-well plates as an additional method of platelet reactivity testing. Platelets 2011; 22(7)485–94
   PubMed Web of Science ®Google Scholar
• Chan MV, Warner TD. Standardised optical multichannel (optimul) platelet aggregometry using high-speed shaking and fixed time point readings. Platelets 2011, doi:10.3109/09537104.09532011.09603066. Epub ahead of print
   Google Scholar
• Peace AJ, Egan K, Kavanagh GF, Tedesco AF, Foley DP, Dicker P, Berndt MC, Kenny D. Reducing intra-individual variation in platelet aggregation: Implications for platelet function testing. J Thromb Haemost 2009; 7(11)1941–1943
   PubMedGoogle Scholar
• Mylotte D, Peace AJ, Tedesco AT, Mangiacapra F, Dicker P, Kenny D, Foley DP. Clopidogrel discontinuation and platelet reactivity following coronary stenting. J Thromb Haemost 2011; 9(1)24–32
   PubMedGoogle Scholar
• Peace AJ, Tedesco AF, Foley DP, Dicker P, Berndt MC, Kenny D. Dual antiplatelet therapy unmasks distinct platelet reactivity in patients with coronary artery disease. J Thromb Haemost 2008; 6(12)2027–2034
   PubMedGoogle Scholar
• Cardinal DC, Flower RJ. The electronic aggregometer: A novel device for assessing platelet behavior in blood. J Pharmacol Methods 1980; 3(2)135–158
   PubMedGoogle Scholar
• Nicholson NS, Panzer-Knodle SG, Haas NF, Taite BB, Szalony JA, Page JD, Feigen LP, Lansky DM, Salyers AK. Assessment of platelet function assays. Am Heart J 1998; 135(5 Pt 2 Su)S170–S178
   Web of Science ®Google Scholar
• Seyfert UT, Haubelt H, Vogt A, Hellstern P. Variables influencing Multiplate(TM) whole blood impedance platelet aggregometry and turbidimetric platelet aggregation in healthy individuals. Platelets 2007; 18(3)199–206
   PubMed Web of Science ®Google Scholar
• Mueller T, Dieplinger B, Poelz W, Calatzis A, Haltmayer M. Utility of whole blood impedance aggregometry for the assessment of clopidogrel action using the novel Multiplate analyzer – Comparison with two flow cytometric methods. Thromb Res 2007; 121(2)249–258
   PubMedGoogle Scholar
• Paniccia R, Antonucci E, Maggini N, Romano E, Gori AM, Marcucci R, Prisco D, Abbate R. Assessment of platelet function on whole blood by multiple electrode aggregometry in high-risk patients with coronary artery disease receiving antiplatelet therapy. Am J Clin Pathol 2009; 131(6)834–842
   PubMed Web of Science ®Google Scholar
• Valarche V, Desconclois C, Boutekedjiret T, Dreyfus M, Proulle V. Multiplate whole blood impedance aggregometry: A new tool for von Willebrand disease. J Thromb Haemost 2011; 9(8)1645–1647
   PubMedGoogle Scholar
• Solomon C, Traintinger S, Ziegler B, Hanke A, Rahe-Meyer N, Voelckel W, Schochl H. Platelet function following trauma. A multiple electrode aggregometry study. Thromb Haemost 2011; 106(2)322–330
   PubMed Web of Science ®Google Scholar
• Johnson A, Dovlatova N, Heptinstall S. Multiple electrode aggregometry and P2Y(12) antagonists. Thromb Haemost 2008; 99(6)1127–1129
   PubMed Web of Science ®Google Scholar
• Haubelt H, Anders C, Hellstern P. Can platelet function tests predict the clinical efficacy of aspirin?. Semin Thromb Hemost 2005; 31(4)404–410
   PubMedGoogle Scholar
• Stissing T, Dridi NP, Ostrowski SR, Bochsen L, Johansson PI. The influence of low platelet count on whole blood aggregometry assessed by Multiplate. Clin Appl Thromb Hemost 2011; 17(6)E211–7
   PubMed Web of Science ®Google Scholar
• McGlasson DL, Fritsma GA. Whole blood platelet aggregometry and platelet function testing. Semin Thromb Hemost 2009; 35(2)168–180
   PubMed Web of Science ®Google Scholar
• Ranucci M, Baryshnikova E, Soro G, Ballotta A, De Benedetti D, Conti D. Multiple electrode whole-blood aggregometry and bleeding in cardiac surgery patients receiving thienopyridines. Ann Thorac Surg 2011; 91(1)123–129
   PubMed Web of Science ®Google Scholar
• Hofer CK, Zollinger A, Ganter MT. Perioperative assessment of platelet function in patients under antiplatelet therapy. Expert Rev Med Dev 2010; 7(5)625–637
   PubMed Web of Science ®Google Scholar
• Breet NJ, van Werkum JW, Bouman HJ, Kelder JC, ten Berg JM, Hackeng CM. High on-aspirin platelet reactivity as measured with aggregation-based, cyclooxygenase-1 inhibition sensitive platelet function tests is associated with the occurrence of atherothrombotic events. J Thromb Haemost 2010; 8(10)2140–2148
   PubMedGoogle Scholar
• Paniccia R, Antonucci E, Maggini N, Miranda M, Gori AM, Marcucci R, Giusti B, Balzi D, Prisco D, Abbate R. Comparison of methods for monitoring residual platelet reactivity after clopidogrel by point-of-care tests on whole blood in high-risk patients. Thromb Haemost 2010; 104(2)287–292
   PubMedGoogle Scholar
• Sibbing D, Braun S, Jawansky S, Vogt W, Mehilli J, Schomig A, Kastrati A, von Beckerath N. Assessment of ADP-induced platelet aggregation with light transmission aggregometry and multiple electrode platelet aggregometry before and after clopidogrel treatment. Thromb Haemost 2008; 99(1)121–126
   PubMed Web of Science ®Google Scholar
• Velik-Salchner C, Maier S, Innerhofer P, Streif W, Klingler A, Kolbitsch C, Fries D. Point-of-care whole blood impedance aggregometry versus classical light transmission aggregometry for detecting aspirin and clopidogrel: The results of a pilot study. Anesth Analg 2008; 107(6)1798–1806
   PubMed Web of Science ®Google Scholar
• Hazarbasanov D, Velchev V, Finkov B, Postadjian A, Kostov E, Rifai N, Aradi D. Tailoring clopidogrel dose according to multiple electrode aggregometry decreases the rate of ischemic complications after percutaneous coronary intervention. J Thromb Thrombolysis 2012; 34(1)85–90
   PubMed Web of Science ®Google Scholar
• Bernlochner I, Morath T, Brown PB, Zhou C, Baker BA, Gupta N, Jakubowski JA, Winters KJ, Schomig A, Kastrati A, et al. A prospective randomized trial comparing the recovery of platelet function after loading dose administration of prasugrel or clopidogrel. Platelets 2012, Epub ahead of print
   Google Scholar
• van Werkum JW, Harmsze AM, Elsenberg EH, Bouman HJ, ten Berg JM, Hackeng CM. The use of the VerifyNow system to monitor antiplatelet therapy: A review of the current evidence. Platelets 2008; 19(7)479–488
   PubMed Web of Science ®Google Scholar
• Michelson AD, Frelinger AL, III, Furman MI. Current options in platelet function testing. Am J Cardiol 2006; 98(10A)4N–10N
   Google Scholar
• Jakubowski JA, Zhou C, Egan B, Wells M, Kotob-Yahfoufi M, Sugidachi A, Dahlen JR. Modification of the VerifyNow(R) P2Y12 test BASE channel to accommodate high levels of P2Y(12) antagonism. Platelets 2011; 22(8)619–625
   PubMed Web of Science ®Google Scholar
• Wang JC, Ucoin-Barry D, Manuelian D, Monbouquette R, Reisman M, Gray W, Block PC, Block EH, Ladenheim M, Simon DI. Incidence of aspirin nonresponsiveness using the Ultegra Rapid Platelet Function Assay-ASA. Am J Cardiol 2003; 92(12)1492–1494
   PubMed Web of Science ®Google Scholar
• Malinin A, Pokov A, Swaim L, Kotob M, Serebruany V. Validation of a VerifyNow-P2Y12 cartridge for monitoring platelet inhibition with clopidogrel. Methods Find Exp Clin Pharmacol 2006; 28(5)315–322
   PubMedGoogle Scholar
• Malinin A, Pokov A, Spergling M, Defranco A, Schwartz K, Schwartz D, Mahmud E, Atar D, Serebruany V. Monitoring platelet inhibition after clopidogrel with the VerifyNow-P2Y12(R) rapid analyzer: The VERIfy Thrombosis risk ASsessment (VERITAS) study. Thromb Res 2007; 119(3)277–284
   PubMed Web of Science ®Google Scholar
• van Werkum JW, van der Stelt CA, Seesing TH, Hackeng CM, ten Berg JM. A head-to-head comparison between the VerifyNow P2Y12 assay and light transmittance aggregometry for monitoring the individual platelet response to clopidogrel in patients undergoing elective percutaneous coronary intervention. J Thromb Haemost 2006; 4(11)2516–2518
   PubMedGoogle Scholar
• Paniccia R, Antonucci E, Gori AM, Marcucci R, Giglioli C, Antoniucci D, Gensini GF, Abbate R, Prisco D. Different methodologies for evaluating the effect of clopidogrel on platelet function in high-risk coronary artery disease patients. J Thromb Haemost 2007; 5(9)1839–1847
   PubMed Web of Science ®Google Scholar
• Jakubowski JA, Payne CD, Li YG, Brandt JT, Small DS, Farid NA, Salazar DE, Winters KJ. The use of the VerifyNow P2Y12 point-of-care device to monitor platelet function across a range of P2Y12 inhibition levels following prasugrel and clopidogrel administration. Thromb Haemost 2008; 99(2)409–415
   PubMed Web of Science ®Google Scholar
• Bidet A, Jais C, Puymirat E, Coste P, Nurden A, Jakubowski J, Nurden P. VerifyNow and VASP phosphorylation assays give similar results for patients receiving clopidogrel, but they do not always correlate with platelet aggregation. Platelets 2010; 21(2)94–100
   PubMed Web of Science ®Google Scholar
• Gaglia MA, Torguson R, Pakala R, Xue Z, Sardi G, Suddath WO, Kent KM, Satler LF, Pichard AD, Waksman R. Correlation between light transmission aggregometry, VerifyNow P2Y12, and VASP-P platelet reactivity assays following percutaneous coronary intervention. J Interv Cardiol 2011; 24(6)529–534
   PubMed Web of Science ®Google Scholar
• Buch AN, Singh S, Roy P, Javaid A, Smith KA, George CE, Pichard AD, Satler LF, Kent KM, Suddath WO, et al. Measuring aspirin resistance, clopidogrel responsiveness, and postprocedural markers of myonecrosis in patients undergoing percutaneous coronary intervention. Am J Cardiol 2007; 99(11)1518–1522
   PubMedGoogle Scholar
• Cuisset T, Hamilos M, Sarma J, Sarno G, Wyffels E, Vanderheyden M, Barbato E, Bartunek J, De Bruyne B, Wijns W. Relation of low response to clopidogrel assessed with point-of-care assay to periprocedural myonecrosis in patients undergoing elective coronary stenting for stable angina pectoris. Am J Cardiol 2008; 101(12)1700–1703
   PubMedGoogle Scholar
• Patti G, Nusca A, Mangiacapra F, Gatto L, D’Ambrosio A, Di Sciascio G. Point-of-care measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention results of the ARMYDA-PRO (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity Predicts Outcome) study. J Am Coll Cardiol 2008; 52(14)1128–1133
   PubMed Web of Science ®Google Scholar
• Brar SS, ten Berg J, Marcucci R, Price MJ, Valgimigli M, Kim HS, Patti G, Breet NJ, DiSciascio G, Cuisset T, et al. Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention. A collaborative meta-analysis of individual participant data. J Am Coll Cardiol 2011; 58(19)1945–1954
   PubMed Web of Science ®Google Scholar
• Patti G, Pasceri V, Vizzi V, Ricottini E, Di Sciascio G. Usefulness of platelet response to clopidogrel by point-of-care testing to predict bleeding outcomes in patients undergoing percutaneous coronary intervention (from the Antiplatelet Therapy for Reduction of Myocardial Damage During Angioplasty-Bleeding Study). Am J Cardiol 2011; 107(7)995–1000
   PubMed Web of Science ®Google Scholar
• Price MJ, Berger PB, Teirstein PS, Tanguay JF, Angiolillo DJ, Spriggs D, Puri S, Robbins M, Garratt KN, Bertrand OF, et al. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: The GRAVITAS randomized trial. JAMA 2011; 305(11)1097–1105
   PubMed Web of Science ®Google Scholar
• Price MJ, Angiolillo DJ, Teirstein PS, Lillie E, Manoukian SV, Berger PB, Tanguay JF, Cannon CP, Topol EJ. Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: A time-dependent analysis of the Gauging Responsiveness with a VerifyNow P2Y12 assay, Impact on Thrombosis and Safety (GRAVITAS) trial. Circulation 2011; 124(10)1132–1137
   PubMed Web of Science ®Google Scholar
• Trenk D, Stone GW, Gawaz M, Kastrati A, Angiolillo DJ, Muller U, Richardt G, Jakubowski JA, Neumann FJ. A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: Results of the TRIGGER-PCI (Testing platelet reactivity in patients undergoing elective stent placement on clopidogrel to guide alternative therapy with prasugrel) study. J Am Coll Cardiol 2012; 59(24)2159–64
   PubMed Web of Science ®Google Scholar
• Campbell J, Ridgway H, Carville D. Plateletworks: A novel point of care platelet function screen. Mol Diagn Ther 2008; 12(4)253–258
   PubMedGoogle Scholar
• Fox SC, Burgess-Wilson M, Heptinstall S, Mitchell JR. Platelet aggregation in whole blood determined using the Ultra-Flo 100 Platelet Counter. Thromb Haemost 1982; 48(3)327–329
   PubMedGoogle Scholar
• Heptinstall S, Fox S, Crawford J, Hawkins M. Inhibition of platelet aggregation in whole blood by dipyridamole and aspirin. Thromb Res 1986; 42(2)215–223
   PubMedGoogle Scholar
• Blais N, Pharand C, Lordkipanidzé M, Sia YK, Merhi Y, Diodati JG. Response to aspirin in healthy individuals. Cross-comparison of light transmission aggregometry, VerifyNow system, platelet count drop, thromboelastography (TEG) and urinary 11-dehydrothromboxane B(2). Thromb Haemost 2009; 102(2)404–411
   PubMed Web of Science ®Google Scholar
• Lordkipanidzé M, Pharand C, Schampaert E, Palisaitis DA, Diodati JG. Evaluation of the platelet count drop method for assessment of platelet function in comparison with “gold standard” light transmission aggregometry. Thromb Res 2009; 124(4)418–422
   PubMedGoogle Scholar
• Carville DG, Schleckser PA, Guyer KE, Corsello M, Walsh MM. Whole blood platelet function assay on the ICHOR point-of-care hematology analyzer. J Extra Corpor Technol 1998; 30(4)171–177
   PubMedGoogle Scholar
• Craft RM, Chavez JJ, Snider CC, Muenchen RA, Carroll RC. Comparison of modified Thrombelastograph and Plateletworks whole blood assays to optical platelet aggregation for monitoring reversal of clopidogrel inhibition in elective surgery patients. J Lab Clin Med 2005; 145(6)309–315
   PubMed Web of Science ®Google Scholar
• White MM, Krishnan R, Kueter TJ, Jacoski MV, Jennings LK. The use of the point of care Helena ICHOR/Plateletworks and the Accumetrics Ultegra RPFA for assessment of platelet function with GPIIB-IIIa antagonists. J Thromb Thrombol 2004; 18(3)163–169
   PubMedGoogle Scholar
• Lennon MJ, Gibbs NM, Weightman WM, McGuire D, Michalopoulos N. A comparison of Plateletworks and platelet aggregometry for the assessment of aspirin-related platelet dysfunction in cardiac surgical patients. J Cardiothorac Vasc Anesth 2004; 18(2)136–140
   PubMedGoogle Scholar
• van Werkum JW, Kleibeuker M, Postma S, Bouman HJ, Elsenberg EH, ten Berg JM, Hackeng CM. A comparison between the Plateletworks-assay and light transmittance aggregometry for monitoring the inhibitory effects of clopidogrel. Int J Cardiol 2010; 140(1)123–126
   PubMed Web of Science ®Google Scholar
• Linden MD, Frelinger AL, III, Barnard MR, Przyklenk K, Furman MI, Michelson AD. Application of flow cytometry to platelet disorders. Semin Thromb Hemost 2004; 30(5)501–511
   PubMed Web of Science ®Google Scholar
• Michelson AD, Furman MI. Laboratory markers of platelet activation and their clinical significance. Curr Opin Hematol 1999; 6(5)342–348
   PubMedGoogle Scholar
• Schmitz G, Rothe G, Ruf A, Barlage S, Tschope D, Clemetson KJ, Goodall AH, Michelson AD, Nurden AT, Shankey TV. European Working Group on Clinical Cell Analysis: Consensus protocol for the flow cytometric characterisation of platelet function. Thromb Haemost 1998; 79(5)885–896
   PubMed Web of Science ®Google Scholar
• Michelson AD. Flow cytometry: A clinical test of platelet function. Blood 1996; 87(12)4925–4936
   PubMed Web of Science ®Google Scholar
• Matzdorff A. Platelet function tests and flow cytometry to monitor antiplatelet therapy. Semin Thromb Hemost 2005; 31(4)393–399
   PubMedGoogle Scholar
• Frelinger AL, 3rd, Michelson AD, Wiviott SD, Trenk D, Neumann FJ, Miller DL, Jakubowski JA, Costigan TM, McCabe CH, Antman EM, et al. Intrinsic platelet reactivity before P2Y12 blockade contributes to residual platelet reactivity despite high-level P2Y12 blockade by prasugrel or high-dose clopidogrel. Results from PRINCIPLE-TIMI 44. Thromb Haemost 2011; 106(2)219–226
   Google Scholar
• Frelinger AL, 3rd, Barnard MR, Fox ML, Michelson AD. The platelet activity after clopidogrel termination (PACT) study. Circ Cardiovasc Interv 2010; 3(5)442–449
   PubMedGoogle Scholar
• Michelson AD, Linden MD, Furman MI, Li Y, Barnard MR, Fox ML, Lau WC, McLaughlin TJ, Frelinger AL. Evidence that pre-existent variability in platelet response to ADP accounts for ‘clopidogrel resistance’. J Thromb Haemost 2007; 5(1)75–81
   PubMedGoogle Scholar
• Fox SC, May JA, Shah A, Neubert U, Heptinstall S. Measurement of platelet P-selectin for remote testing of platelet function during treatment with clopidogrel and/or aspirin. Platelets 2009; 20(4)250–259
   PubMed Web of Science ®Google Scholar
• Barragan P, Bouvier JL, Roquebert PO, Macaluso G, Commeau P, Comet B, Lafont A, Camoin L, Walter U, Eigenthaler M. Resistance to thienopyridines: Clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation. Catheter Cardiovasc Interv 2003; 59(3)295–302
   PubMed Web of Science ®Google Scholar
• El Ghannudi S, Ohlmann P, Meyer N, Wiesel ML, Radulescu B, Chauvin M, Bareiss P, Gachet C, Morel O. Impact of P2Y12 inhibition by clopidogrel on cardiovascular mortality in unselected patients treated by percutaneous coronary angioplasty: A prospective registry. JACC Cardiovasc Interv 2010; 3(6)648–656
   PubMedGoogle Scholar
• Bonello L, Camoin-Jau L, Arques S, Boyer C, Panagides D, Wittenberg O, Simeoni MC, Barragan P, Dignat-George F, Paganelli F. Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: A multicenter randomized prospective study. J Am Coll Cardiol 2008; 51(14)1404–1411
   PubMed Web of Science ®Google Scholar
• Bonello L, Camoin-Jau L, Armero S, Com O, Arques S, Burignat-Bonello C, Giacomoni MP, Bonello R, Collet F, Rossi P, et al. Tailored clopidogrel loading dose according to platelet reactivity monitoring to prevent acute and subacute stent thrombosis. Am J Cardiol 2009; 103(1)5–10
   PubMed Web of Science ®Google Scholar
• Wang XD, Zhang DF, Liu XB, Lai Y, Qi WG, Luo Y, Hu B, Yao YA. Modified clopidogrel loading dose according to platelet reactivity monitoring in patients carrying ABCB1 variant alleles in patients with clopidogrel resistance. Eur J Int Med 2012; 23(1)48–53
   PubMed Web of Science ®Google Scholar
• Freynhofer MK, Bruno V, Willheim M, Hubl W, Wojta J, Huber K. Vasodilator-stimulated phosphoprotein-phosphorylation assay in patients on clopidogrel: Does standardisation matter?. Thromb Haemost 2012; 107(3)538–544
   PubMedGoogle Scholar
• Barragan P, Paganelli F, Camoin-Jau L, Bourguet N, Boulay-Moine D, Moulard M, Bonello L. Validation of a novel ELISA-based VASP whole blood assay to measure P2Y12-ADP receptor activity. Thromb Haemost 2010; 104(2)410–411
   PubMedGoogle Scholar
• Harrison P. The role of PFA-100 testing in the investigation and management of haemostatic defects in children and adults. Br J Haematol 2005; 130(1)3–10
   PubMed Web of Science ®Google Scholar
• Favaloro EJ. Clinical utility of the PFA-100. Semin Thromb Hemost 2008; 34(8)709–733
   PubMed Web of Science ®Google Scholar
• Kundu SK, Heilmann EJ, Sio R, Garcia C, Davidson RM, Ostgaard RA. Description of an in vitro platelet function analyzer – PFA-100. Semin Thromb Hemost 1995; 21(Suppl 2)106–112
   PubMed Web of Science ®Google Scholar
• Kundu SK, Heilmann EJ, Sio R, Garcia C, Ostgaard RA. Characterization of an in vitro platelet function analyzer – PFA-100. Clin Appl Thromb Hemost 1996; 2: 241–249
   Web of Science ®Google Scholar
• Favaloro EJ. Utility of the PFA-100 for assessing bleeding disorders and monitoring therapy: A review of analytical variables, benefits and limitations. Haemophilia 2001; 7(2)170–179
   PubMed Web of Science ®Google Scholar
• Homoncik M, Jilma B, Hergovich N, Stohlawetz P, Panzer S, Speiser W. Monitoring of aspirin (ASA) pharmacodynamics with the platelet function analyzer PFA-100. Thromb Haemost 2000; 83(2)316–321
   PubMed Web of Science ®Google Scholar
• Chakroun T, Gerotziafas G, Robert F, Lecrubier C, Samama MM, Hatmi M, Elalamy I. In vitro aspirin resistance detected by PFA-100 closure time: Pivotal role of plasma von Willebrand factor. Br J Haematol 2004; 124(1)80–85
   PubMedGoogle Scholar
• Andersen K, Hurlen M, Arnesen H, Seljeflot I. Aspirin non-responsiveness as measured by PFA-100 in patients with coronary artery disease. Thromb Res 2002; 108(1)37–42
   PubMed Web of Science ®Google Scholar
• Hayward CP, Harrison P, Cattaneo M, Ortel TL, Rao AK. Platelet function analyzer (PFA)-100 closure time in the evaluation of platelet disorders and platelet function. J Thromb Haemost 2006; 4(2)312–319
   PubMed Web of Science ®Google Scholar
• Pidcock M, Harrison P. Can the PFA-100 be modified to detect P2Y12 inhibition?. J Thromb Haemost 2006; 4(6)1424–1426
   PubMedGoogle Scholar
• Jilma B. Synergistic antiplatelet effects of clopidogrel and aspirin detected with the PFA-100 in stroke patients. Stroke 2003; 34(4)849–854
   PubMedGoogle Scholar
• Koessler J, Kobsar AL, Rajkovic MS, Schafer A, Flierl U, Pfoertsch S, Bauersachs J, Steigerwald U, Rechner AR, Walter U. The new INNOVANCE PFA P2Y cartridge is sensitive to the detection of the P2Y12 receptor inhibition. Platelets 2011; 22: 19–25
   Web of Science ®Google Scholar
• Linnemann B, Schwonberg J, Rechner AR, Mani H, Lindhoff-Last E. Assessment of clopidogrel non-response by the PFA-100 system using the new test cartridge INNOVANCE PFA P2Y. Ann Hematol 2010; 89(6)597–605
   PubMed Web of Science ®Google Scholar
• Edwards A, Jakubowski JA, Rechner AR, Sugidachi A, Harrison P. Evaluation of the INNOVANCE PFA P2Y test cartridge: Sensitivity to P2Y(12) blockade and influence of anticoagulant. Platelets 2012; 23(2)106–15
   PubMed Web of Science ®Google Scholar
• Carcao MD, Blanchette VS, Stephens D, He L, Wakefield CD, Butchart S, Christie DJ, Rand ML. Assessment of thrombocytopenic disorders using the Platelet Function Analyzer (PFA-100). Br J Haematol 2002; 117(4)961–964
   PubMed Web of Science ®Google Scholar
• Favaloro EJ. Clinical application of the PFA-100. Curr Opin Hematol 2002; 9(5)407–415
   PubMed Web of Science ®Google Scholar
• Jilma B. Platelet function analyzer (PFA-100): A tool to quantify congenital or acquired platelet dysfunction. J Lab Clin Med 2001; 138(3)152–163
   PubMedGoogle Scholar
• Hartert H. Thrombelastography: A method for physical analysis of blood coagulation. Z Gesamte Exp Med 1951; 117(2)189–203
   PubMedGoogle Scholar
• Luddington RJ. Thrombelastography/thromboelastometry. Clin Lab Haematol 2005; 27(2)81–90
   PubMedGoogle Scholar
• Salooja N, Perry DJ. Thrombelastography. Blood Coag Fibrinol 2001; 12(5)327–337
   PubMed Web of Science ®Google Scholar
• Chen A, Teruya J. Global hemostasis testing thromboelastography: Old technology, new applications. Clin Lab Med 2009; 29(2)391–407
   PubMed Web of Science ®Google Scholar
• Scharbert G, Auer A, Kozek-Langenecker S. Evaluation of the platelet mapping assay on rotational thromboelastometry ROTEM. Platelets 2009; 20(2)125–130
   PubMed Web of Science ®Google Scholar
• Craft RM, Chavez JJ, Bresee SJ, Wortham DC, Cohen E, Carroll RC. A novel modification of the Thrombelastograph assay, isolating platelet function, correlates with optical platelet aggregation. J Lab Clin Med 2004; 143(5)301–309
   PubMed Web of Science ®Google Scholar
• Hobson AR, Agarwala RA, Swallow RA, Dawkins KD, Curzen NP. Thrombelastography: Current clinical applications and its potential role in interventional cardiology. Platelets 2006; 17(8)509–518
   PubMed Web of Science ®Google Scholar
• Bochsen L, Wiinberg B, Kjelgaard-Hansen M, Steinbruchel DA, Johansson PI. Evaluation of the TEG platelet mapping assay in blood donors. Thromb J 2007; 5: 3–7
   PubMedGoogle Scholar
• Chitlur M, Sorensen B, Rivard GE, Young G, Ingerslev J, Othman M, Nugent D, Kenet G, Escobar M, Lusher J. Standardization of thromboelastography: A report from the TEG-ROTEM working group. Haemophilia 2011; 17(3)532–537
   PubMed Web of Science ®Google Scholar
• Afshari A, Wikkelso A, Brok J, Moller AM, Wetterslev J. Thrombelastography (TEG) or thromboelastometry (ROTEM) to monitor haemotherapy versus usual care in patients with massive transfusion. Cochrane Database Syst Rev 2011; 3: 1–63:CD007871
   Google Scholar
• Morton J, Nelluri S. Use of a thrombelastograph platelet mapping assay for diagnosis of clopidogrel resistance: A case report. J Extra Corpor Technol 2009; 41(1)32–36
   PubMedGoogle Scholar
• Sambu N, Radhakrishnan A, Dent H, Calver AL, Corbett S, Gray H, Simpson IA, Curzen N. Personalised antiplatelet therapy in stent thrombosis: Observations from the Clopidogrel Resistance in Stent Thrombosis (CREST) registry. Heart 2012; 98(9)706–711
   PubMed Web of Science ®Google Scholar
• Spectre G, Brill A, Gural A, Shenkman B, Touretsky N, Mosseri E, Savion N, Varon D. A new point-of-care method for monitoring anti-platelet therapy – Application of the cone and plate(let) analyzer. Platelets 2005; 16(5)293–299
   PubMedGoogle Scholar
• Kenet G, Lubetsky A, Shenkman B, Tamarin I, Dardik R, Rechavi G, Barzilai A, Martinowitz U, Savion N, Varon D. Cone and platelet analyser (CPA): A new test for the prediction of bleeding among thrombocytopenic patients. Br J Haematol 1998; 101(2)255–259
   PubMed Web of Science ®Google Scholar
• Varon D, Lashevski I, Brenner B, Beyar R, Lanir N, Tamarin I, Savion N. Cone and plate(let) analyzer: Monitoring glycoprotein IIb/IIIa antagonists and von Willebrand disease replacement therapy by testing platelet deposition under flow conditions. Am Heart J 1998; 135(5)S187–S193
   PubMedGoogle Scholar
• Shenkman B, Savion N, Dardik R, Tamarin I, Varon D. Testing of platelet deposition on polystyrene surface under flow conditions by the cone and plate(let) analyzer: Role of platelet activation, fibrinogen and von Willebrand factor. Thromb Res 2000; 99(4)353–361
   PubMedGoogle Scholar
• Varon D, Dardik R, Shenkman B, Kotev-Emeth S, Farzame N, Tamarin I, Savion N. A new method for quantitative analysis of whole blood platelet interaction with extracellular matrix under flow conditions. Thromb Res 1997; 85(4)283–294
   PubMed Web of Science ®Google Scholar
• van Werkum JW, Bouman HJ, Breet NJ, ten Berg JM, Hackeng CM. The Cone-and-Plate(let) analyzer is not suitable to monitor clopidogrel therapy: A comparison with the flowcytometric VASP assay and optical aggregometry. Thromb Res 2010; 126(1)44–49
   PubMedGoogle Scholar
• Furie B, Furie BC. Thrombus formation in vivo. J Clin Invest 2005; 115(12)3355–3362
   PubMed Web of Science ®Google Scholar
• Phillips DR, Conley PB, Sinha U, Andre P. Therapeutic approaches in arterial thrombosis. J Thromb Haemost 2005; 3(8)1577–1589
   PubMedGoogle Scholar
• Tovar-Lopez FJ, Rosengarten G, Westein E, Khoshmanesh K, Jackson SP, Mitchell A, Nesbitt WS. A microfluidics device to monitor platelet aggregation dynamics in response to strain rate micro-gradients in flowing blood. Lab Chip 2010; 10(3)291–302
   PubMed Web of Science ®Google Scholar
• Hosokawa K, Ohnishi T, Kondo T, Fukasawa M, Koide T, Maruyama I, Tanaka KA. A novel automated microchip flow-chamber system to quantitatively evaluate thrombus formation and antithrombotic agents under blood flow conditions. J Thromb Haemost 2011; 9: 2029–2037
   PubMed Web of Science ®Google Scholar
• Kent NJ, O’Brien S, Basabe-Desmonts L, Meade GR, MacCraith BD, Corcoran BG, Kenny D, Ricco AJ. Shear-mediated platelet adhesion analysis in less than 100 mul of blood: Toward a POC platelet diagnostic. IEEE Trans Biomed Eng 2011; 58(3)826–830
   PubMedGoogle Scholar
• Basabe-Desmonts L, Meade G, Kenny D. New trends in bioanalytical microdevices to assess platelet function. Expert Rev Mol Diagn 2010; 10(7)869–874
   PubMed Web of Science ®Google Scholar
• Lincoln B, Ricco AJ, Kent NJ, Basabe-Desmonts L, Lee LP, MacCraith BD, Kenny D, Meade G. Integrated system investigating shear-mediated platelet interactions with von Willebrand factor using microliters of whole blood. Anal Biochem 2010; 405(2)174–183
   PubMedGoogle Scholar
• Gutierrez E, Petrich BG, Shattil SJ, Ginsberg MH, Groisman A, Kasirer-Friede A. Microfluidic devices for studies of shear-dependent platelet adhesion. Lab Chip 2008; 8(9)1486–1495
   PubMed Web of Science ®Google Scholar
• Neeves KB, Maloney SF, Fong KP, Schmaier AA, Kahn ML, Brass LF, Diamond SL. Microfluidic focal thrombosis model for measuring murine platelet deposition and stability: PAR4 signaling enhances shear-resistance of platelet aggregates. J Thromb Haemost 2008; 6(12)2193–2201
   PubMed Web of Science ®Google Scholar
• Conant CG, Nevill JT, Zhou Z, Dong JF, Schwartz MA, Ionescu-Zanetti C. Using well-plate microfluidic devices to conduct shear-based thrombosis assays. J Lab Autom 2011; 16(2)148–152
   PubMedGoogle Scholar
• Johnson GJ, Sharda AV, Rao GH, Ereth MH, Laxson DD, Owen WG. Measurement of shear-activated platelet aggregate formation in non-anticoagulated blood: Utility in detection of clopidogrel-aspirin-induced platelet dysfunction. Clin Appl Thromb Hemost 2012; 18(2)140–149
   PubMedGoogle Scholar
• Mega JL, Simon T, Collet JP, Anderson JL, Antman EM, Bliden K, Cannon CP, Danchin N, Giusti B, Gurbel P, et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: A meta-analysis. JAMA 2010; 304(16)1821–1830
   PubMed Web of Science ®Google Scholar
• Sofi F, Giusti B, Marcucci R, Gori AM, Abbate R, Gensini GF. Cytochrome P450 2C19*2 polymorphism and cardiovascular recurrences in patients taking clopidogrel: A meta-analysis. Pharmacogenomics J 2011; 11(3)199–206
   PubMed Web of Science ®Google Scholar
• Hulot JS, Collet JP, Silvain J, Pena A, Bellemain-Appaix A, Barthelemy O, Cayla G, Beygui F, Montalescot G. Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration: A systematic meta-analysis. J Am Coll Cardiol 2010; 56(2)134–143
   PubMed Web of Science ®Google Scholar
• Mega JL, Hochholzer W, Frelinger AL, 3rd, Kluk MJ, Angiolillo DJ, Kereiakes DJ, Isserman S, Rogers WJ, Ruff CT, Contant C, et al. Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease. JAMA 2011; 306(20)2221–2228
   PubMed Web of Science ®Google Scholar
• Harmsze AM, van Werkum JW, Hackeng CM, Ruven HJ, Kelder JC, Bouman HJ, Breet NJ, ten Berg JM, Klungel OH, de Boer A, et al. The influence of CYP2C19*2 and *17 on on-treatment platelet reactivity and bleeding events in patients undergoing elective coronary stenting. Pharmacogenet Genomics 2012; 22(3)169–175
   PubMed Web of Science ®Google Scholar
• Nissen SE. Pharmacogenomics and clopidogrel: Irrational exuberance?. JAMA 2011; 306(24)2728–2727
   Google Scholar
• Bauer T, Bouman HJ, van Werkum JW, Ford NF, ten Berg JM, Taubert D. Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: Systematic review and meta-analysis. BMJ 2011; 343: 1–8:d4588
   Google Scholar
• Holmes MV, Perel P, Shah T, Hingorani AD, Casas JP. CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: A systematic review and meta-analysis. JAMA 2011; 306(24)2704–2714
   PubMed Web of Science ®Google Scholar
• Roberts JD, Wells GA, Le May MR, Labinaz M, Glover C, Froeschl M, Dick A, Marquis JF, O’Brien E, Goncalves S, et al. Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): A prospective, randomised, proof-of-concept trial. Lancet 2012; 379(9827)1705–11
   PubMed Web of Science ®Google Scholar
• Buchan BW, Peterson JF, Cogbill CH, Anderson DK, Ledford JS, White MN, Quigley NB, Jannetto PJ, Ledeboer NA. Evaluation of a microarray-based genotyping assay for the rapid detection of cytochrome P450 2C19 *2 and *3 polymorphisms from whole blood using nanoparticle probes. Am J Clin Pathol 2011; 136(4)604–608
   PubMedGoogle Scholar
• Saracini C, Vestrini A, Galora S, Armillis A, Abbate R, Giusti B. Pharmacogenetics of clopidogrel: Comparison between a standard and a rapid genetic testing. Genet Test Mol Biomarkers 2012; 16(6)500–3
   PubMed Web of Science ®Google Scholar
• Beitelshees AL. Personalised antiplatelet treatment: A RAPIDly moving target. Lancet 2012; 379(9827)1680–2
   PubMedGoogle Scholar
• Buchanan GL, Basavarajaiah S, Chieffo A. Stent thrombosis: Incidence, predictors and new technologies. Thrombosis 2012; 2012: 956–962
   Google Scholar
• Marcucci R, Giusti B, Paniccia R, Gori AM, Saracini C, Valente S, Giglioli C, Parodi G, Antoniucci D, Gensini GF, et al. High on-treatment platelet reactivity by ADP and increased risk of MACE in good clopidogrel metabolizers. Platelets 2012, Epub ahead of print
   PubMedGoogle Scholar
• Siller-Matula JM, Delle-Karth G, Lang IM, Neunteufl T, Kozinski M, Kubica J, Maurer G, Linkowska K, Grzybowski T, Huber K, et al. Phenotyping vs. genotyping for prediction of clopidogrel efficacy and safety: The PEGASUS-PCI study. J Thromb Haemost 2012; 10(4)529–542
   PubMedGoogle Scholar
• Sibbing D, Byrne RA, Kastrati A. Role of platelet function testing in clinical practice: Current concepts and future perspectives. Curr Drug Targets 2011; 12(12)1836–1847
   PubMedGoogle Scholar